Wellness Franchise Opportunities

MergerMar, 09 2015

Apex court of Punjab and Haryana orally approves Ranbaxy, Sun Pharma merger

Sun Pharma announced the $4 billion deal to buy Ranbaxy in April 2014. One year down the line, the High Courts of Punjab and Haryana have orally approved the merger of the pharma majors.

By Agencies

Approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries, the High Court of Punjab and Haryana has orally approved the merger of two biggies.

According to Sun Pharmaceutical, a certified true copy of the court order is awaited.

Reportedly, the US Federal Trade Commission (FTC) recently approved the proposed $4-billion buyout of Ranbaxy by Sun Pharma. It completed its review of the deal and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

FTC accepted a proposed consent agreement following which Sun Pharma and Ranbaxy have agreed to divest Ranbaxy’s interests in generic minocycline tablets and capsules to an external third party.

Generic minocycline tablets are used to treat an array of bacterial infections, including pneumonia, acne and urinary tract infections.

In December, the Indian fair trade regulator Competition Commission of India (CCI) had approved the mega deal with certain riders. As per the conditions, CCI directed both the companies to divest seven products as it found that the deal could hit competition in the Indian market.

Last April, Sun Pharma announced that it would take control on Ranbaxy in an all-stock transaction with a total equity value of $3.2 billion, along with debt of $800 million, taking the overall deal value to $4 billion.

This would be the biggest domestic Merger & Acquisition (M&A) deal ever and by far the top Pharma deal in local currency terms.

Significantly, once completed, the deal would create India’s largest and world’s fifth-biggest drug maker with operations across 65 countries, 47 manufacturing facilities in five continents and a global portfolio of specialty and generic products.

Related: Sun Pharma to delist Ranbaxy from BSE post completion of $4 billion merger

Click Here to add Comment
Please add your Comment
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.


Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.

Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.